Organ transplant device manufacturer Transmedics, Inc. announced on 7 September that the US Food and Drug Administration approved a PMA for the company’s OCS Heart System.
The system is used to preserve for transplant hearts harvested from donors who have experienced brain death. It’s specifically designated for use in preserving and reviving hearts initially considered unsuitable...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?